NEXT day delivery available - 3pm cut off
Worldwide shipping available
Free standard UK delivery on orders over £100
This article is intended for qualified aesthetic practitioners. It is educational and does not replace manufacturer instructions for use (IFU), your training or your own clinical judgement.
Polynucleotides under eyes work best on a specific kind of problem: thin, crepey, finely lined lower-lid skin where the issue is tissue quality rather than missing volume. Used on the right patient, at the right depth, as a planned course, they give you a regenerative option for the periorbital area that carries none of the oedema or Tyndall risk that comes with hyaluronic acid in the tear trough. Used on the wrong patient, they disappoint, because no amount of polynucleotide will fill a deep hollow or hide a prolapsed fat pad.
Below we cover how to select patients, how the main eye-specific polynucleotide products differ, injection technique and depth, how to plan a course, and where a polynucleotide eye treatment sits alongside tear trough filler.
Polynucleotides (PN) are purified DNA fragments, usually derived from salmon or trout, supplied as an injectable gel. Unlike cross-linked HA filler they are not designed to add structural volume. Manufacturers describe their role as supporting fibroblast activity and the extracellular matrix, with the aim of improving skin thickness, elasticity and hydration over a period of weeks.
That mechanism suits the lower eyelid well. The skin there is among the thinnest on the face, sits over orbicularis oculi with very little subcutaneous fat, and shows every irregularity. Patients often describe their concern as "dark circles", but on examination the problem is frequently translucent skin showing the underlying muscle and vasculature, plus fine crepey lines. That is the presentation where polynucleotides have the most to offer.
Most disappointing outcomes come from selection rather than technique. Before you reach for a syringe, work out what is actually driving the patient's concern.
Because PN is fish-derived, a documented fish or seafood allergy is a key exclusion. Also screen for pregnancy and breastfeeding, active infection or inflammation at the site, and any other contraindications listed in the specific product's IFU. Patients who avoid animal-derived products for personal reasons should be told the source at consultation. Record all of this in your consent documentation.
Several brands make a dedicated periorbital formulation, usually at a lower concentration or with different rheology from their full-face product. The figures below come from each product's listing. Always confirm against the current IFU for the batch you hold.
Concentration is not a direct proxy for "strength" or results, so don't read it that way. What it does change is how the product behaves in the syringe, how readily it forms a papule, and how much you can comfortably place in thin tissue. Many practitioners keep one product they know well for routine periorbital work rather than rotating brands, so their technique and patient advice stay consistent. The full range is in our polynucleotides and PDRN collection, and our earlier comparison of polynucleotide brands covers the full-face products.
Photograph the patient in consistent lighting, both with the eyes open and looking up. Cleanse thoroughly with an appropriate antiseptic, and keep it away from the eye itself. Apply topical anaesthesia according to your clinic protocol and prescribing arrangements. Have the patient seated at roughly 45 degrees so that the tear trough and lid–cheek junction are visible as they would be upright.
Most eye-specific PN products are designed for superficial intradermal placement with a fine needle, usually 30G or finer. The most common approach is a grid of small micro-papules or micro-boluses across the treatment zone, spaced evenly, with small aliquots at each point. You should see a small, transient bleb form. If no bleb appears, you are probably too deep.
Practical points that make a difference:
Some practitioners deliver PN to the tear trough with a fine cannula, using linear retrograde threading in a superficial plane from a lateral entry point. This can mean fewer entry points and less bruising, but it gives less control over very superficial placement, and you need to be confident with periorbital cannula work. Check whether your chosen product's IFU supports this route. If you are choosing cannula gauge and length, our cannula buying guide covers sizing.
Polynucleotides are a course treatment, not a single appointment. UK clinics commonly run an initial series of two to four sessions spaced a few weeks apart, followed by periodic maintenance. The exact protocol should follow the IFU for the product you use. Set this out at consultation, in writing, so the patient understands that change is gradual and will not be visible at the first review.
A simple structure many clinics use:
These are not competing treatments. They solve different problems, and for many patients the best plan uses both in sequence.
If you combine the two, separate them by an appropriate interval, and document which product went where and at what depth.
The small blebs from intradermal PN are expected and usually settle within a day or two. Pinpoint redness and some bruising are possible, especially in patients with visible periorbital vessels. Give written aftercare that covers:
Be careful with how you describe expected outcomes. Talk about improving skin quality over a course, not guaranteed results, and avoid before-and-after promises in your consultation materials as well as your marketing.
When a trained practitioner uses a product indicated for the periorbital area, at the correct superficial depth, in a properly screened patient, polynucleotides are generally well tolerated. Common effects are transient papules, redness and bruising. The main screening points are fish or seafood allergy, pregnancy and breastfeeding, and active skin infection. As with any periorbital injectable, anatomy knowledge and a complications plan are essential.
They can improve skin quality concerns such as crepiness, fine lines and thinness, which is what they are designed for. They do not replace volume, so patients with a deep tear trough hollow or fat pad prolapse will not see the change they expect from a booster alone. Most disappointing results come down to patient selection.
Most clinic protocols advise leaving the treated area alone for the rest of the day, then cleansing gently from the following day. Give the specific timing in your written aftercare, in line with the product IFU and your clinic protocol.
Polynucleotides are not a filler that "wears off" in the same way HA does. The aim is a gradual improvement in tissue quality, which is then supported with maintenance sessions. How long an improvement lasts varies between patients and is affected by age, skin condition, sun exposure and lifestyle. Set maintenance intervals according to the product guidance and each patient's response.
Polynucleotides under eyes earn their place when the problem is skin quality: thin, crepey, translucent lower-lid skin that you would hesitate to load with HA. Assess carefully, choose an eye-specific product you know well, inject superficially, and plan a proper course with honest expectations, and they become one of the most useful tools you have for the periorbital area. When the real issue is volume or fat pad prolapse, recognise it early and offer the treatment, or the referral, that will actually help.
